 |
|
Cost Sharing and the Initiation of Drug Therapy for the Chronically Ill
Matthew D. Solomon, MD, PhD;
Dana P. Goldman, PhD;
Geoffrey F. Joyce, PhD;
José J. Escarce, MD, PhD
Arch Intern Med. 2009;169(8):740-748.
Background Increased cost sharing reduces utilization of prescription drugs, but little evidence demonstrates how this reduction occurs or the factors associated with price sensitivity.
Methods We conducted a retrospective cohort study of older adults with employer-provided drug coverage from 1997 to 2002 from 31 different health plans. We measured the time until initiation of medical therapy for 17 183 patients with newly diagnosed hypertension, diabetes, or hypercholesterolemia.
Results For all study conditions, higher copayments were associated with delayed initiation of therapy. In survival models, doubling copayments resulted in large reductions in the predicted proportion of patients initiating pharmacotherapy at 1 and 5 years after diagnosis: for hypertension, 54.8% vs 39.9% at 1 year and 81.6% vs 66.2% at 5 years (P < .001); for hypercholesterolemia, 40.2% vs 31.1% at 1 year and 64.3% vs 53.8% at 5 years (P < .002); and for diabetes, 45.8% vs 40.0% at 1 year and 69.3% vs 62.9% at 5 years (P < .04). However, patients' rate of initiation and sensitivity to copayments strongly depended on their prior experience with prescription drugs. Those without prior drug use (26.1%, 10.4%, and 12.9%) initiated later (833, >1170, and >1402 days later in median time until initiation) and were far more price sensitive (increase of 34.5%, 20.1%, and 27.2% remaining untreated after 5 years when copayments doubled) than those with a history of drug use among patients with newly diagnosed hypertension, hypercholesterolemia, and diabetes, respectively. These results were robust to a wide range of sensitivity analyses.
Conclusions High cost sharing delays the initiation of drug therapy for patients newly diagnosed with chronic disease. This effect is greater among patients who lack experience with prescription drugs. Policy makers and physicians should consider the effects of benefits design on patient behavior to encourage the adoption of necessary care.
Author Affiliations: Department of Medicine, Stanford University School of Medicine, Stanford, California (Dr Solomon); RAND Corporation, Santa Monica, California (Drs Solomon, Goldman, Joyce, and Escarce); and Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles (Dr Escarce).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
In This Issue of Archives of Internal Medicine
Arch Intern Med. 2009;169(8):736.
FULL TEXT
The Change We Need in Health Care
David C. Goff, Jr and Philip Greenland
Arch Intern Med. 2009;169(8):737-739.
EXTRACT
| FULL TEXT
Cost Sharing and the Initiation of Drug Therapy for the Chronically Ill—Invited Commentary
Sumit R. Majumdar
Arch Intern Med. 2009;169(8):748-749.
EXTRACT
| FULL TEXT
Prior Authorization for Antidepressants in Medicaid: Effects Among Disabled Dual Enrollees
Alyce S. Adams, Fang Zhang, Robert F. LeCates, Amy Johnson Graves, Dennis Ross-Degnan, Daniel Gilden, Thomas J. McLaughlin, Christine Lu, Connie M. Trinacty, and Stephen B. Soumerai
Arch Intern Med. 2009;169(8):750-756.
ABSTRACT
| FULL TEXT
Effect of a Pharmacist on Adverse Drug Events and Medication Errors in Outpatients With Cardiovascular Disease
Michael D. Murray, Mary E. Ritchey, Jingwei Wu, and Wanzhu Tu
Arch Intern Med. 2009;169(8):757-763.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A model for NICE in the US
Ferner and McDowell
BMJ 2009;338:b2221-b2221.
FULL TEXT
Effect of Out-of-Pocket Drug Expenses on Initiation of Drug Therapy
JWatch General 2009;2009:10-10.
FULL TEXT
The Change We Need in Health Care
Goff and Greenland
Arch Intern Med 2009;169:737-739.
FULL TEXT
|
